Streetwise Expert Interviews

Vernon Bernardino

Biotechs with Upside Possibilities Target Ebola and Liver Disease: MLV & Co.'s Vernon Bernardino

Everybody knows that biotech ideas can become huge gainers for investors, but understanding the technology platforms, the unmet needs and the valuations can be daunting, especially in spaces where a number of players are developing products. In this interview with The Life Sciences Report, Vernon Bernardino of MLV & Co. brings some clarity and perspective to investors who could reap windfalls from small-cap names in which shareholder value has yet to be created and realized. (9/10/14) More >


Read more Streetwise Interviews. . .

including Steve Brozak: Big-Picture Biotech Stocks Rule the Future (9/4/14) More >

Newsletter Briefs

"IMNP's bertilimumab is a powerful antibody." (9/10/14) Immune Pharmaceuticals Inc. - The Life Sciences Report Interview with Vernon Bernardino More >

"I expect results from NBS' Phase 2 PreSERVE-AMI trial in Q4/14; that will be proof of concept for this approach." (9/10/14) NeoStem Inc. - The Life Sciences Report Interview with Vernon Bernardino More >

"IPD's device allows the physician to detect lymphedema 200 days earlier than with a tape measure." (8/28/14) ImpediMed Ltd. - The Life Sciences Report Interview with Matthijs Smith More >

"There's more to OMER than Omidria; the company has quite a pipeline." (8/21/14) Omeros Corp. - The Life Sciences Report interview with Liana Moussatos More >

"MDXG provides better, faster and cheaper technology compared to current wound-care therapies." (8/19/14) MiMedx Group Inc. - William Plovanic, Canaccord Genuity More >

"CUR has two very credible shots on goal." (8/13/14) Neuralstem Inc. - The Life Sciences Report Interview with Raghuram Selvaraju More >

"ARNI's onapristone could potentially be a suprabillion-dollar drug upon approval." (8/13/14) Arno Therapeutics Inc. - The Life Sciences Report Interview with Raghuram Selvaraju More >

"RP is at the forefront of the utilization of stem cells to treat disorders and defects." (8/7/14) RepliCel Life Sciences Inc. - The Life Sciences Report Interview with Mark Landy More >

Expert Analysis

"NEO is one of the best-positioned and managed high-complexity oncology reference labs." (9/10/14) NeoGenomics Laboratories - Debjit Chattopadhyay, ROTH Capital Partners More >

"IPD's appointment of Dr. Frank Vicini should raise L-Dex's profile." (9/8/14) ImpediMed Ltd. - Matthijs Smith, Canaccord Genuity More >

"STEM will be first to initiate a controlled Phase 2 study using human neural stem cells." (9/8/14) StemCells Inc. - Christopher James, Brinson Patrick Securities Corporation More >

"We are initiating coverage on CUR." (9/8/14) Neuralstem Inc. - Reni Benjamin, H.C. Wainwright & Co. More >

"RNN ended Q2/14 with $38.3M cash, providing it sufficient runway into H2/16." (9/8/14) Rexahn Pharmaceuticals Inc. - Christopher James, Brinson Patrick Securities Corporation More >

"We are initiating coverage on THLD with a Buy rating." (9/5/14) Threshold Pharmaceuticals Inc. - Andrew Fein, H.C. Wainwright & Co. More >

"IPD has had a transformational event; we increase our price target for the company." (9/5/14) ImpediMed Ltd. - Scott Power, Morgans More >

"RXII should have preliminary Phase 2a trial data by end of September." (9/3/14) RXi Pharmaceuticals Corp. - Edward White, Laidlaw & Company More >